Pfizer (PFE) Options Premium Income: Plays for a Beaten-Down Pharma Giant

Why PFE Premiums Are Elevated

Pfizer has been in a downtrend since the post-COVID revenue cliff. Shares sit around $27, down from $50+ at the 2022 peak. But the decline created something options sellers love: elevated implied volatility on a stock with strong fundamental support below.

PFE's IV runs 28-35%, well above what you would expect from a mega-cap pharma company. The reasons: pipeline uncertainty (will the obesity drug work?), patent cliffs on key products, and ongoing debate about whether the COVID vaccine franchise has any residual value.

For sellers, PFE at $27 with 30%+ IV is a compelling setup. The stock is cheap enough that further downside is limited (4.5% dividend yield provides support), and the premiums compensate generously for the risks.

Income Strategies

Covered Calls on PFE

With PFE at $27, here is the premium landscape:

| Strike | DTE | Premium | Annualized | $28.5030$0.55~24% $29.0030$0.38~17% $28.5045$0.75~22% | $30.00 | 45 | $0.42 | ~12% |

The $28.50 strike at 30 DTE collects $0.55, giving you a 24% annualized yield. That is exceptional for a pharma blue chip. The catch: PFE could rally sharply on positive pipeline news, and you would miss the upside above $28.50.

Selling Puts at Support

PFE has established strong support in the $24-25 range. Selling the $25 put (7.4% OTM) for 30 DTE collects approximately $0.35-0.45.

At $25, Pfizer's dividend yield would be over 5%, which attracts institutional income buyers and creates a natural floor. If assigned, you own a top-5 pharma company at a 5%+ yield with covered call opportunities above.

The Dividend Factor

PFE pays $0.42 quarterly ($1.68 annually) for a yield around 6.2% at current prices. This dividend is a crucial part of the income strategy.

Annual income stack:

  • Dividend: $1.68 per share (6.2%)
  • Covered call premium (11 months): ~$5.00-6.00 per share (18-22%)
  • Total income: $6.68-7.68 per share (24.7-28.4%)

    • Even if PFE stock goes nowhere for a year, you earn nearly 25% income. That is the power of combining elevated IV with a high dividend yield.

    Managing Pipeline Risk

    Pharma stocks carry binary event risk. An FDA approval or rejection can move PFE 5-10% overnight. Clinical trial readouts are unpredictable.

    Rules for PFE options sellers:

  • Check the FDA calendar and clinical trial milestone dates before selling. Avoid having short options expiring within a week of major readouts.
  • Use defined-risk spreads around binary events. The $25/$22 put spread collects less than a naked put but limits your downside to $3 per share.
  • Accept that one positive catalyst could blow through your call strike. If PFE pops on a successful Phase 3 trial, your called-away shares might miss a 15% rally. That is the cost of doing business.

    • Is PFE a Value Trap?

    The bear case: revenue continues declining as COVID products fade, the pipeline fails to replace lost revenue, and the stock drifts to $22-24. In this scenario, your put selling gets you assigned at progressively lower prices.

    The bull case: the pipeline delivers, the obesity drug gains traction, and PFE rebounds to $35+. Your covered calls cap upside, but you still earn 30%+ annualized from premiums plus dividends on the way up.

    The options seller's edge: You profit in both the sideways and modestly bullish scenarios, which historically cover about 70% of outcomes for a stable pharma stock. The extreme bear case is your real risk, and position sizing protects you there.

    OptionsPilot helps you screen PFE options by income yield and IV percentile, flagging when premiums are at the rich end of their historical range.